Download MendeleyDiscovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.
Halkina, T., Henderson, J.L., Lin, E.Y., Himmelbauer, M.K., Jones, J.H., Nevalainen, M., Feng, J., King, K., Rooney, M., Johnson, J.L., Marcotte, D.J., Chodaparambil, J.V., Kumar, P.R., Patterson, T.A., Murugan, P., Schuman, E., Wong, L., Hesson, T., Lamore, S., Bao, C., Calhoun, M., Certo, H., Amaral, B., Dillon, G.M., Gilfillan, R., de Turiso, F.G.(2021) J Med Chem 64: 6358-6380
- PubMed: 33944571
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00382
- Primary Citation of Related Structures:
7JXX, 7JXY - PubMed Abstract:
Structural analysis of the known NIK inhibitor 3 bound to the kinase domain of TTBK1 led to the design and synthesis of a novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC 50 : 571 nM). Systematic optimization of this series of analogs led to the discovery of 31 , a potent (cell IC 50 : 315 nM) and selective TTBK inhibitor with suitable CNS penetration (rat K p,uu : 0.32) for in vivo proof of pharmacology studies. The ability of 31 to inhibit tau phosphorylation at the disease-relevant Ser 422 epitope was demonstrated in both a mouse hypothermia and a rat developmental model and provided evidence that modulation of this target may be relevant in the treatment of Alzheimer's disease and other tauopathies.
Organizational Affiliation:
Department of Medicinal Chemistry, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States.
